Don't forget to register for our June 27th virtual investor event where we will review new clinical data on our lead product candidate from our ongoing Phase 2 trial in #ChronicNeutropenia. We are excited to include renowned experts Dr. Jean Donadieu, MD, PhD, and Dr. Peter E. Newburger, MD, who will share their insights on the interim results and the high unmet need in CN. Register now by clicking the link here: https://bit.ly/3VuyTQu #Progress4Patients
X4 Pharmaceuticals’ Post
More Relevant Posts
-
Exciting week to talk about #scleroderma and rare musculoskeletal diseases. Hopefully see many of you in Prague! #clinicaltrials #imaging #cartcelltherapy #innovation #pharma #biotechnology
📢 𝗝𝘂𝘀𝘁 𝗮 𝗳𝗲𝘄 𝗱𝗮𝘆𝘀 𝗹𝗲𝗳𝘁 𝗯𝗲𝗳𝗼𝗿𝗲 𝘁𝗵𝗲 𝟴𝘁𝗵 𝗦𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗦𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 Meet Dr. Olga Kubassova, President of IAG, and Francesco Del Galdo, Scientific Advisory Board Member and Expert in Scleroderma Clinical Research, to discuss how the team leverages its expertise to optimize clinical trials outcomes. To book a meeting with us, reach out to: imaging.experts@ia-grp.com #scleroderma #clinicaltrials #rarediseases #research World Scleroderma Foundation
To view or add a comment, sign in
-
SVP Global Life Sciences Practice at TransPerfect Life Sciences | Improving and Expediting Global Product Launch
Check out the recording of our session with Kate Shaw, Founder and CEO of Innovative Trials and Leanne Woehlke, Director of Life Science Solutions at TPT. This webinar examines current challenges to meeting and retaining recruitment numbers, and how clinical sites can strive to ensure patients are kept at the core of their operations. https://lnkd.in/ezaiA6A5 #patientengagement #clinicaltrials #webinar
Didn't get a chance to catch our webinar on keeping patients at the heart of clinical trials last week? Watch on-demand our conversation with Kate Shaw, Founder and CEO of Innovative Trials, and Leanne Woehlke, Director of Life Science Solutions at TransPerfect Life Sciences. This comprehensive session delved into the current clinical research landscape, and strategies to overcome the challenges facing trial sites in recruiting and retaining patients. Access the recording here: https://lnkd.in/eMZw2C-F #PatientEngagement #ClinicalTrials #Webinar
To view or add a comment, sign in
-
Consilium Scientific in conversation with Frank Harrell: Modernizing Clinical Trial Design and Analysis to Improve Efficiency & Flexibility. This talk covers several ways to make clinical trials more efficient and to reduce the chance of ending with an equivocal result. Some of the approaches covered are Bayesian sequential designs allowing for study extension if results are promising, not being tied by type I assertion probabilities/α spending, using high-information longitudinal ordinal outcomes, and covariate adjustment.
Frank Harrell: Modernizing Clinical Trial Design & Analysis
www.linkedin.com
To view or add a comment, sign in
-
Don't miss the FINAL part of our three-part series "Thriving in Clinical Research - Overcoming Common Challenges as a Site." This final session addresses a top site challenge identified in our 2023 Site Challenges Survey: Site Capacity. Hear from industry experts to learn about core considerations for trial success and discover proven solutions to increase trial efficiency and drive transformative results for participants. Join us December 5th, register now at https://lnkd.in/g_49pQpi #ClinicalResearch #SiteChallenges #SiteResourcing
To view or add a comment, sign in
-
Senior Medical Director at FutureMeds; Founder (1995) and Director of Krakow Medical Centre (up to 2020)
THE RIGHT ANSWER: DEDICATED RESEARCH SITE I fully agree with Torsten Sernau, that today's dedicate d Reseacr site sa is the right response to the changes being made in the field of clinical research. I started my research in 1994. I was the site of one doctor, one nurse, one assistant. This was enough to carry out three protocols three protocols in ibandronate clinicnal trial. At that time, the CRF was 25 pages long and the central documentation was fed into a single CRO computer from carbon copy extracted from the CRF of the local centers. Currently, CRF takes several hundred or even more pages and often does not fit in one binder. Hence, in 2020, there were 12 doctors and 4 nurses working in my center and 4 coordinators, plus others. Projects are becoming more and more complex and their implementation consumes a huge amount of working time. The only answer to the situation is a Dedicated Research Site.
When starting out in clinical research in the mid-1990s, Torsten Sernau, MD saw the potential of an emerging model, the Dedicated Research Site. It set the bar for trial productivity. Close to 30 years later, with a wealth of expertise and experience behind Torsten’s back, his passion for the model just grew. And the challenges since the pandemic have only amplified the importance of DRS: - Healthcare appointment backlogs across major healthcare systems - Doubled healthcare staff turnover during the pandemic, with slow recovery - Declining clinical trial capacity in academic centres and hospitals due to staffing challenges - Tripling R&D spending over the past 20 years - Surge in clinical studies (from 325,000 in 2021 to over 440,000 in 2023) - Increasingly complex trial protocols - Expanding disease phenotypes Given these trends, the drawbacks faced by traditional trial settings are evident. "𝙁𝙚𝙬𝙚𝙧 𝙧𝙚𝙨𝙤𝙪𝙧𝙘𝙚𝙨 𝙛𝙤𝙧 𝙢𝙤𝙧𝙚 𝙬𝙤𝙧𝙠 𝙘𝙖𝙣𝙣𝙤𝙩 𝙡𝙚𝙖𝙙 𝙩𝙤 𝙥𝙤𝙨𝙞𝙩𝙞𝙫𝙚 𝙤𝙪𝙩𝙘𝙤𝙢𝙚𝙨. 𝙏𝙝𝙞𝙨 𝙞𝙨 𝙬𝙝𝙚𝙧𝙚 𝙙𝙚𝙙𝙞𝙘𝙖𝙩𝙚𝙙 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙨𝙞𝙩𝙚𝙨 𝙨𝙩𝙚𝙥 𝙞𝙣. 𝙏𝙝𝙚𝙮 𝙤𝙥𝙚𝙧𝙖𝙩𝙚 𝙞𝙣𝙙𝙚𝙥𝙚𝙣𝙙𝙚𝙣𝙩𝙡𝙮 𝙤𝙛 𝙧𝙤𝙪𝙩𝙞𝙣𝙚 𝙘𝙖𝙧𝙚 𝙖𝙣𝙙 𝙚𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚𝙡𝙮 𝙚𝙣𝙜𝙖𝙜𝙚 𝙬𝙞𝙩𝙝 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙩𝙝𝙧𝙤𝙪𝙜𝙝𝙤𝙪𝙩 𝙩𝙝𝙚𝙞𝙧 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙩𝙧𝙞𝙖𝙡 𝙟𝙤𝙪𝙧𝙣𝙚𝙮." For details, read Torsten's article here: https://lnkd.in/eZGVH_ns #ClinicalTrials #ClinicalResearch
To view or add a comment, sign in
-
Results presented at the ESC HFA 2024 late breaker clinical trial session on May 11th! A consistent effect of PA guided therapy across predefined subgroups within and across clinical endpoint categories of QoL, HFH and mean PAP in the MONITOR-HF trial. Please find the draft manuscript simultaneously published in European Heart Journal! https://lnkd.in/eXVk66g5
To view or add a comment, sign in
-
Read about the latest developments in the NVG-291 clinical study and how you may qualify to be a participant. There's also info in this article on how to listen to the interview on Curecast with Dr. Monica Perez, a clinician-scientist at the Shirley Ryan AbilityLab in Chicago, who discusses this exciting trial in more detail. Check it out HERE - https://bit.ly/48jace5
To view or add a comment, sign in
-
Past President Argentine Lipid Society. Internal Medicine physician and Lipidologist. Pharmacology Professor at FASTA University, School of Medicine.
👉2️⃣0️⃣1️⃣5️⃣, International Atherosclerosis Society (IAS) meeting in #amsterdan 😯My first poster about Lp(a) 5️⃣ patients with very high levels of Lp(a) and different clinical manifestations 💪It is fantastic to see today, 8️⃣years later, many presentations and how science has advanced
To view or add a comment, sign in
-
https://lnkd.in/e-h3sXjZ In honor of #labweek2024 - a reminder about how vitally important our lab professionals are to innovating the future of so many industries - in this case #diagnosticmedicine. Their efforts to provide critical answers every day should always be celebrated! "Since the pandemic, the awareness of the importance of the lab has grown significantly. Here are just a few of the impacts: -70% of today’s medical decisions depend on laboratory test results. -260,000 CLIA-certified laboratories across the U.S. represent the cornerstone of diagnostic medicine today. -14 billion laboratory tests are ordered annually — safety, quality, and cost-effectiveness in laboratory testing are required for effective diagnosis and treatment of disease." Future Labs Live USA #FutureLabsLive #LabWeek #labinnovation #labtesting #labsafety #labquality #healthandmedicine
Lab Week 2024 - Insights
news.mayocliniclabs.com
To view or add a comment, sign in
10,462 followers